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Abstract: The HIV/AIDS pandemic is one of the most devastating pandemics worldwide. 
Today, the major route of infection by HIV is sexual transmission. One of the most 
promising strategies for vaccination against HIV sexual infection is the development of a 
mucosal vaccine, which should be able to induce strong local and systemic protective 
immunity. It is believed that both humoral and cellular immune responses are needed for 
inducing a sterilizing protection against HIV. Recently, passive administration of 
monoclonal neutralizing antibodies in macaques infected by vaginal challenge 
demonstrated a crucial role of FcRs in the protection afforded by these antibodies. This 
questioned about the role of innate and adaptive immune functions, including ADCC, 
ADCVI, phagocytosis of opsonized HIV particles and the production of inflammatory 
cytokines and chemokines, in the mechanism of HIV inhibition in vivo. Other monoclonal 
antibodies - non-neutralizing inhibitory antibodies - which recognize immunogenic 
epitopes, have been shown to display potent FcRs-dependent inhibition of HIV 
replication  in vitro. The potential role of these antibodies in protection against sexual 
transmission of HIV and their biological relevance for the development of an HIV vaccine 
therefore need to be determined. This review highlights the potential role of FcRs-
mediated innate and adaptive immune functions in the mechanism of HIV protection. 
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1. Introduction 
Currently, one estimates at more than 40 million the number of people living with HIV/AIDS in the 
world. AIDS is and remains one of the principal causes of death worldwide (more than 33 million 
people have died from the infection since the discovery of HIV). Each year, two to three million 
individuals become infected worldwide, corresponding to about 7,500 new cases of infection per day 
(Report on the Global AIDS Epidemic Geneva; UNAIDS; 2008.). The number of people infected has 
stabilized since 2008, but the HIV/AIDS epidemic cannot yet be considered to be under control. 
Despite efforts to develop effective anti-retroviral drugs, many infected individuals have no access to 
treatment with multi-drug regimens. The development of a prophylactic vaccine is, thus, still a matter 
of priority, if we are to limit the pandemic. Today, the majority of the people infected by HIV are 
women (in India, Latin America, North America, Thailand, China and East Europe) and the 
heterosexual transmission of HIV via the genital mucosae has become the major mode of infection. In 
more than 80% of newly diagnosed cases of HIV-1 infection, the patients were infected during sexual 
intercourse. Currently, one of the innovating vaccination strategies would consist in developing a 
mucosal vaccine as an effective means of prevention against HIV sexual transmission. Such a vaccine 
should stimulate the production of particular antibodies, mucosal HIV-specific antibodies (mainly, IgG 
and secretory IgA) that are able to neutralize free viral particles and to inhibit infection of mucosal 
HIV target cells before the establishment of systemic infection, in addition to a strong induction of 
cellular immunity. Such antibodies, by preventing the infection of the first target cells of the virus such 
as immature dendritic cells and resident macrophages, localized in the vaginal mucosa (epithelium and 
submucosal sites), constitute a first line of defense against the virus at this portal of entry. These key 
cells of the anti-infectious immunity are described to be permissive to HIV in vitro, being infected in 
vivo and producing de novo viral particles [1-4]. Many recent works have highlighted the central role 
of these antigen-presenting cells (APCs) in HIV pathogenesis. In vitro, these dendritic cells have been 
shown to transfer infectious viral particles to nearby CD4 T lymphocytes in trans [3-7]. Cell-to-cell 
transmission of HIV has been proposed to be a very efficient mode of infection and to participate to 
the dissemination of the virus throughout the body. It is believed that antibodies, which neutralize HIV 
infection of these primary target cells, constitute one of the components of the immune response to 
induce by vaccination. However, only 10 to 20% of the patients develop antibodies able to neutralize a 
broad spectrum of primary isolates of HIV [8]. These types of antibody are only seldom detected after 
vaccination in the conventional neutralization assay. After several years of intensive research, only a 
small number of neutralizing monoclonal antibodies that inhibit a broad spectrum of HIV primary 
isolates were described to date. The neutralizing activity of these antibodies has been evaluated in vitro 
during the infection of primary blood CD4 T lymphocytes (the principal target cells of HIV) [9] and, 
more recently, with human cell lines expressing receptor and co-receptor of HIV [10]. Several studies 
largely showed that the passive transfer of neutralizing antibodies, i.e., antibodies able to inhibit the Viruses 2009, 1                  
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viral replication in vitro, make it possible to protect the macaques from an experimental infection with 
chimerical viruses (SHIV) [11-15]. Recently, it has been demonstrated that Fc portion of neutralizing 
monoclonal IgG1 b12 is crucially involved in the mechanism of HIV protection mediated by passive 
administration of this neutralizing IgG after vaginal SHIV challenge in non-human primate model: 
indicating that FcRs are important in HIV protection by neutralizing antibodies [13]. However, the 
Fc-mediated inhibitory activity of HIV-specific antibodies was not well evaluated in vitro; for 
instance, the activity of HIV-specific antibodies (neutralizing versus non-neutralizing IgG) on HIV 
replication in other human primary target cells such as macrophages [16,17] and dendritic cells [18,19] 
was been little studied and are poorly understood. Recently, antibodies that differ from neutralizing 
antibodies, referred to as unconventional antiviral or non-neutralizing inhibitory antibodies (reviewed 
in [20]) have been described to play a potent role in the inhibition of HIV replication in these APCs 
[21-23]. These antibodies could represent new additional antibodies to induce by vaccinal 
immunization. In the present review, certain aspects concerning HIV inhibition by antibodies such as 
neutralization and Fc-mediated inhibitory activity will be discuss, and consequences for the 
development of new vaccination strategies will be highlighted. 
2. IgG structure and functions  
Table 1. IgG glycosylation and effector functions. Human IgG are glycoproteins with a 
sugar moiety attached to the constant Fc region. The IgG-Fc region is a homodimer 
consisting of an inter-chain disulfide-bonded hinge region and glycosylated CH2 domains 
bearing an N-linked oligosaccharide at Asn297 (as shown in the figure). The sugar residues 
are shown in color and form the core structure oligosaccharide. Arrows indicate enzymatic 
cleavage sites used to generate various truncated glycoforms. This glycan core is essential 
for maintaining a stable and functional Fc structure, a prerequisite for IgG-mediated FcR 
effector functions. However, variations in the composition of the sugar moiety may 
influence Fc-FcR interaction and activity. Thus, the nature of antibody glycosylation may 
alter IgG binding to activating or inhibitory FcRs. Not all Fc-FcR interactions are 
equally affected by changes in IgG-Fc glycosylation. IgG-Fc glycosylation may regulate 
activating and inhibitory Fc effector functions, thereby modulating immunity. This table 
summarizes the influence of the IgG glycosylation on the FcR effector functions [26-29]. 
 Viruses 2009, 1                  
 
 
1268
Table 1. Cont. 
 
Variations in IgG-Fc glycoform  
 
Fc effector binding and functions 
  
 
Complete deglycosylation of IgG1 : 
 
- Loss of FcR binding capacity 
- Failure to initiate effector function  
   
Removal of fucose residues :  - Increase in IgG affinity (all subclasses) for FcRIIIa 
- Enhancement of Fc-FcR interaction  
   
Removal of galactose residues :  - Lower levels of C1q binding to IgG-Fc 
- Either increase or decrease in IgG affinity for FcRs
   
Exposure of N-acetylglucosamine 
residues after galactose removal : 
 
- Increase in MBL binding 
- Observed in some autoimmune diseases 
   
Fc glycan hydrolysis between two N-
acetylglucosamine residues : 
 
- Inhibition of the binding of IgG and C1q to FcRs  
- Abolition of the activation of effector and 
complement functions 
- Impairment of structural stability and functional 
activity 
   
Truncated glycoforms :  - low IgG binding affinity to FcRIIb 
   
Increase of the levels of sialic acid :  - Decrease in FcRIII/IV affinity 
- No change in IgG binding to FcRIIb 
   
Replacement of amino acid residues 
interacting with galactose or N-
acetylglucosamine in the 1-6 arm 
position : 
 
 
 
- No influence in IgG binding to FcRI 
   
Replacement of Asn297 :  - Loss of N-linked glycosylation 
- FcRI affinity halved 
   
Removal of mannose residues in the 
1-6 arm position : 
 
- Impairment of FcRs recognition by IgG 
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Table 1. Cont. 
Different glycosylation pattern 
induced by mammalian cell culture 
systems :  
 
 
- Effects on the biological activity of humanized 
monoclonal antibody 
- Optimization of effector function activity 
 
Sialylated IgG :   - Anti-inflammatory properties 
   
Aberrant IgG-Fc glycoforms :  - Congenital disorders 
   
 
Antibodies, particularly those of the IgG type, are key mediators of the protective humoral 
immunity. IgG and other Ig are composed of constant and variable regions: the antigen binding site 
(Fab) is constituted of the association of variable and constant regions, whereas the so-called Fc 
domain is formed by two constant regions. Through their Fab parts, antibodies recognized specific 
epitopes at the membrane surface of pathogen and through their Fc domain; they act as immune 
response modulators, notably by interacting with Fc receptors (FcRs).  
2.1. Role of Fc glycosylation 
IgG glycosylation has been shown to play a key role in modulating antibody binding to FcRs 
[24,25]. The Fc domain of IgG harbors a sugar moiety, consisting of a conserved biantennary core 
structure with additional fucose and sialic acid residues [26]. Glycosylation of IgG has been shown to 
be essential for binding to FcRs (whether activating or inhibitory) (Table 1). While removal of the 
whole sugar moiety from the Fc part will change its structural integrity [27], resulting in impaired 
binding IgG to FcRs [28], but variations in Fc glycosylation may affect FcR binding in different 
ways [29]. For example, low levels of fucose specifically increase the affinity of IgG for activating 
FcRIIIa [30], a receptor involved in triggering antibody-dependent cell cytotoxicity (ADCC). 
Galactose, another residue in the sugar moiety, has also been implicated in IgG activity. Indeed, some 
autoimmune disorders are associated with increased level of IgG without terminal galactose and sialic 
acid [28]. Conversely, highly sialylated IgG glycoforms display low FcRs binding capacity. Thus, 
IgG enriched with sialic acid had a diminished cytotoxic activity in vivo, consistent with their reduced 
affinity for FcRs. It was demonstrated that sialic acid confers enhanced anti-inflammatory activity to 
IgG via upregulation of inhibitory FcRIIb expression [31]. This receptor has been described to be 
mostly implicated in regulatory function of innate and adaptive immunity [25]. An indirect mechanism 
has been proposed, suggesting that other unknown receptors exist and are able to sense sialic-acid-rich 
IgG [24]. Variations in IgG glycoforms in vivo have been reported upon immunization [32]. IgG 
fucosylation increases in response to repeated immunization with ovalbumin, suggesting that changes 
in IgG fucosylation may be of biological significances. These findings are consistent with the notion 
that antigen-specific antibodies generated in response to immunization acquire the ability to mediate a 
protective inflammatory response through switching to an IgG population with lower levels of Viruses 2009, 1                  
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sialylation. These data open up new possibilities for research aiming to induce the production of 
specific IgG subsets by immunization against HIV. For example, it would be interesting to analyze the 
association of IgG subclasses and Fc domain glycosylation with the HIV inhibitory activities of IgG in 
HIV controllers. In vaccinated HIV individuals, such associations need also to be determined. The role 
of the Fc portion of such antibodies in the immune function need to be investigate and clarify in order 
to design further HIV vaccine candidates that are able to elicit antibodies with optimal FcR 
engagements. 
2.2. Antigen-specific IgG functions 
The antigen-specific IgG specialize in the recognition of pathogenic agents, including HIV-1, and 
trigger various immune functions, such as neutralization, aggregation, phagocytosis, degranulation, 
cellular cytotoxicity (ADCC), virus inhibition (ADCVI or antibody-dependent cell-mediated virus 
inhibition) and the release of pro-inflammatory cytokines or chemokines. These antibodies may 
mediate either pro- or anti- inflammatory effects, by binding to activating or inhibitory FcRs. In vivo, 
immune cell activations or functions are triggered by the engagement of specific FcRs (balanced 
between activating or inhibitory FcRs). These activating and inhibitory FcRs are differentially 
expressed on a wide range of innate immune effector cells, including basophils, mast cells, neutrophils, 
monocytes, macrophages, dendritic cells, eosinophils, neutrophils, NK cells,  T and B lymphocytes 
(reviewed in [33]). The binding of immune complexes to FcRs on dendritic cells or macrophages, for 
example, has been shown to result in the phagocytosis, degradation and presentation of antigenic 
peptide on MHC class I and II molecules (leading to the activation of the other antigen-specific 
immune cells such as CTLs, CD4 T-helper cells, Treg cells, etc.) [34]. Other FcR effector functions 
of have been also described, such as ADCC and ADCVI for instance. As part of humoral immune 
responses, ADCC is a mechanism whereby a FcR-bearing effector cell lysed a target cell that 
expressed foreign antigens, which have been recognized and bound by specific antibodies. Similar to 
ADCC, ADCVI will measure both cytolytic and noncytolytic killing of infected cells by FcR-bearing 
effector cells. NK cells are widely believed to be the major mediators of ADCC in vivo [35,36], but 
others cells of the immunity, in particular monocytes, macrophages [37], neutrophils, eosinophils and 
 T cells have also been described to mediate ADCC [38]. As the large majority of these cells are 
present in different sites, more often in peripheral tissues, they can act early during the initial events of 
the infection. ADCC activity has mainly been attributed to FcRIIIa and IgG1 and IgG3 isotypes. 
FcRIIIa presents at the cell membrane of a subset of NK cells is able to recognize Fc part of IgG 
which its Fab portion will bound to HIV antigen present at the cell membrane of infected target cells. 
Once bound to FcRIII, NK cells released cytokines such as IFN-γ, and cytotoxic granules containing 
perforin and granzymes that promote cell death by triggering apoptosis of the targeted cells. FcRI of 
eosinophils and monocytes can also induce cell death by recognizing IgE-bound cancer cells [39,40]. 
In the case of HIV vaccine development, optimizing HIV-specific antibody activities by enhancing 
their interaction with FcRs would likely to improve the viral fate and disease outcome. It might be 
useful for example to enhance HIV-specific IgG reactions such as antibody-mediated destruction of 
virus-infected cells at mucosal site of viral entry. Moreover, improving HIV antigen presentation by 
using antibody as targeting molecule for the delivery of antigen to specialized APCs via FcRs would Viruses 2009, 1                  
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not only enhance viral degradation but also boost specific antiviral immunity. All these points will 
need to be addressed during the development of an effective HIV vaccine. 
3. Broadly neutralizing antibodies against HIV 
 
Despite intensive research in the field of HIV vaccine development over the last 20 years, only a 
small number of monoclonal antibodies that display highly active broadly neutralizing activity have 
been discovered. These antibodies include five well known neutralizing monoclonal antibodies 
capable of strongly inhibiting the replication of a large spectrum of primary HIV isolates and 
protecting macaques against SHIV infection. Three of these monoclonal antibodies (IgG1 b12, 2G12 
and 447-52D) are directed against specific epitopes of gp120 and the other two (2F5 and 4E10) are 
directed against the membrane-proximal external region (MPER) of gp41 [41-45]. More recent studies, 
based on the use of high-throughput strategies for screening and identifying the neutralizing activities 
of antibodies from HIV patients, have led to the discovery of new additional broadly neutralizing 
monoclonal antibodies [46-48]. 
3.1. Monoclonal neutralizing IgG : IgG1 b12, 2G12, 447-52D, 2F5 and 4E10 
IgG1 b12 was the first neutralizing antibody to be identified. This antibody recognizes the CD4 
receptor-binding site on gp120, which is conserved between various HIV subtypes [39]. IgG1 b12 
showed an unusual protuberance of his paratope that confers such specificity, in particular, to plunge 
in the cavity of the gp120 responsible for the attachment to CD4, inhibiting by this fact the binding of 
HIV to its host receptor. Many other antibodies recognizing epitopes in the vicinity of the CD4 binding 
site have been found in HIV-infected individuals, but none of them exhibited potent neutralizing 
activity [49]. 2G12 recognizes an epitope based on the C4/V4 region of gp120 [50-53]. Conserved 
mannose residues on the distal end of the oligomannose glycan located around the base of the V3 and 
V4 loops in the outer and “silent” face of gp120 are required for 2G12 binding. This epitope is located 
on carbohydrate residues, which are generally poorly immunogenic or even tolerogenic, as HIV used 
host glycosylation machinery. 2G12 is a very interesting and unique antibody, as its structure is 
unconventional and differs from the classical “Y”-shaped form of IgG antibodies in that the two heavy 
structures of the arms are vertically adjacent. This specific configuration enables this antibody to 
display neutralizing activity against many HIV clades [54]. Thus, consistent with the apparently 
unique nature of 2G12, such neutralizing antibodies are difficult to elicit. It has been proposed that this 
antibody may prevent HIV attachment to the CD4 receptor and to alternative receptors, such as DC-
SIGN (by competing with 2G12 for binding to gp120) [50,55], thereby inhibiting non-specific HIV 
fusion. 
447-52D recognizes 14 amino acids, including the conserved stretch of four amino acids - GPGR - 
core sequence at the tip of the hypervariable V3 loop [50]. The conservation of this sequence at the tip 
of the V3 loop is directly related to the function of this loop in binding to the HIV coreceptor. 447-52D 
neutralizes primary isolates bearing the GPGR V3 motif, regardless of whether these viruses belong to 
clades A, B, F, or H. However, this sequence is more highly conserved among subtype B viruses. 
Independently of the CXCR4 and CCR5 coreceptor usage, this neutralizing antibody is able to 
neutralize both R5- and X4-HIV strains. The interaction of 447-52D with the V3 loop seems to be Viruses 2009, 1                  
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unique, as it is not observed with other anti-V3 antibodies. The V3 region of some HIV primary 
isolates is somewhat inaccessible to 447-52D, due to the presence of glycan moieties or V1/V2 
regions, often rendering these viruses resistant to neutralization. Some resistant viruses become 
sensitive to 447-52D neutralization after binding to their receptors. Thus, conformational changes may 
expose critical epitopes, making them accessible for antibody recognition. Such observation has also 
been made for neutralizing CD4 induced antibodies that need HIV binding to its receptor for 
recognizing other neutralizing masked epitopes. 
Monoclonal neutralizing 2F5 and 4E10 recognize a conserved epitope of the HIV gp41 that has 
been directly implicated in viral fusion. 2F5 binds to an epitope involving a linear amino acid motif 
ELDKWA on the gp41. These antibodies cannot prevent HIV attachment to the cells, but a later 
phenomenon of virus-host cell membrane fusion [41]. They were obtained from EBV-immortalized B-
cell clones generated from PBMCs from various HIV-infected subjects [42]. These antibodies have 
been described to have lipid polyreactivity and CDR3 motifs suggestive of autoimmune antibodies 
[56,57]. Their neutralizing activity is mediated by the long CDR3 H3 loop that penetrates deeply into 
the antigen cleft [49]. This has led to the suggestion that immune dysregulation may contribute to the 
development of these MPER antibodies [56,57], accounting for the rarity of 2F5- and 4E10-like 
antibodies in HIV patients. 
3.2. New broadly neutralizing antibodies: recent findings 
By examining neutralization breadth in sera or plasma samples from large cohorts of infected 
individuals, new broadly cross-neutralizing antibodies have been recently discovered [46-48]. Using a 
single round of infection of TZM-bl cells with pseudo-virus particles, as the main neutralization assay 
for the detection of neutralizing antibodies, the group of Lynn Moris has demonstrated that various 
subclasses of IgG directed against a novel epitope within the gp41 MPER have potent heterologous 
neutralizing activity. These antibodies detected in three broadly neutralizing plasma of chronically 
infected individuals, and for one (BB34) of them, were mainly from the IgG3 subclass. Originally, 
4E10, 2F5 and neutralizing fraction of a HIVIG were all of the IgG3 subclass [58,59]. IgG3 antibodies 
appear early in infection and have a very flexible hinge region that is thought to render the MPER 
region highly accessible to these antibodies. However, class switching from IgG3 to IgG1 did not 
affect the neutralizing activity of the well-known neutralizing 2F5 and 4E10 antibodies, indicating a 
lack of requirement of the IgG subclass for MPER-mediated neutralization. Interestingly, like 2F5 and 
4E10, the anti-MPER neutralizing activity detected in BB34 was potentiated by the presence of FcRI 
on TZM-bl, indicating that these new recognized epitopes within the MPER region may confirm the 
relevance of such immunogens for rational vaccine design [60], as FcRs have been shown to play a 
crucial role in the mechanism of protection by neutralizing antibodies in macaques [61]. Further 
evaluations are required to determine whether the subclass (IgG1 or IgG3) of these neutralizing 
antibodies affects their potency in vivo, due to differences in Fc affinity for the corresponding FcRs. 
Although, it has been proposed that such anti-MPER antibodies are autoreactive and therefore 
eliminated through B-cell tolerance mechanisms [56], these data showed that neutralizing anti-MPER 
antibodies are seldom detected in HIV-infected individuals. The presence of anti-MPER antibodies in 
broadly neutralizing blood samples has also been reported [62,63]. These neutralizing antibodies that Viruses 2009, 1                  
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target MPER epitopes overlapping the 2F5 epitope were not produced during the acute phase of 
infection but rather 12 to 27 months following HIV transmission and coincident with the development 
of auto-antibodies. Indeed, others have concluded that the time period following HIV exposure is an 
important parameter that could influence neutralization breadth and antibody avidity [64]. The 
antibody activity or potency to neutralize HIV may also depend of the maturation of its Fab domain 
[65]. Others may assume that post-translational changes in antibody structure would turn a non-
neutralizing antibody into a broadly neutralizing one or enhance the cross-neutralizing activity of weak 
neutralizing antibody. Due to poor immunogenicity of these neutralizing epitopes, we need to identify 
new cross-neutralizing antibodies that would recognize immunogenic epitopes, which are more 
accessible on HIV envelope to facilitate vaccine design. 
The group of Dennis Burton has recently isolated, from an African donor, two potent monoclonal 
antibodies (PG9 and PG16). These antibodies were unable to bind monomeric gp120 and gp41 while 
they neutralize native viral particles. They recognized a new cross-neutralizing epitope expressed on 
the quaternary envelope structure of the conserved region of V2/V3 loops [48]. Their gene analysis 
revealed that these broadly neutralizing antibodies had a long CDR3 loop, typical of polyreactive 
antibody. The reactivity of these antibodies against several antigens was tested and no polyreactivity 
was found. Interestingly, these neutralizing antibodies display different neutralizing activities against 
any given virus. These neutralization data undoubtedly reflect the capacity of the immune system to 
evolve with viral envelope mutations. As these new neutralizing antibodies display broad 
neutralization activities, particularly, against non-clade B HIV primary isolates, they would provide 
protection against the most prevalent HIV variants worldwide if they could be induced by vaccination. 
3.3. In vivo production of neutralizing antibodies: proof-of-concept 
A recent study has demonstrated that the in vivo administration of an adeno-associated virus (AAV) 
vector carrying the gene encoding an engineered neutralizing antibody (distinct from IgG1 b12 and 
2G12) can induce the production of the biologically active neutralizing antibody in the serum of 
macaques and maintained a long-term memory immunity [66]. In the vaccinated monkeys, neutralizing 
antibodies produced in vivo can protect them from an intravenous SIV challenge, at virus inoculum 
concentrations known to infect 100% of the macaques [66]. Such systems have been previously been 
used to generate cross-neutralizing IgG1 b12 production in mouse serum, as a proof-of-concept [67]. 
In addition, memory antibody responses to HIV have recently been characterized, in particular from 
infected patients with low viral loads and broadly neutralizing antibodies [68], suggesting that HIV-
specific humoral immune responses can achieve such neutralizing antibody production. These results 
pave the way for innovative new approaches for the cloning of neutralizing antibodies from HIV 
individuals. Altogether, these data provide new hope for the rational design of new vaccine candidates 
for eliciting broad-range cross-neutralizing antibodies. 
4. Neutralizing IgG as a hallmark of protection against HIV 
The particular hallmarks of humoral immunity to HIV have raised many questions about the role of 
neutralizing antibodies during HIV infection in vivo. In rhesus monkeys, the reduction in the number 
of B lymphocytes delays the appearance of neutralizing antibodies after infection with SIVmac251, but Viruses 2009, 1                  
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has no effect on the initial control of the viral load during early phase of primo-infection [69]. 
Moreover, in non-progressor HIV-patients a strong humoral response made up of neutralizing 
antibodies has been detected associated with the control of viremia [70-72]. 
4.1. Neutralizing antibodies as immune correlates of protection 
Now, there is widespread acceptance that eliciting neutralizing antibodies is likely to be an 
important component of an effective HIV-1 vaccine [73]. The neutralizing activity of antibodies is 
largely considered as the mainstay of antiviral immune protection mediated by Ig. It is well known that 
in vitro HIV-1 neutralization by monoclonal IgG is correlated with in vivo protection against HIV-1 in 
macaque model [12,13,61,74-76]. Several years ago, it was clearly demonstrated that the passive 
administration of a mixture of neutralizing antibodies prevents the vaginal transmission of pathogenic 
chimeric virus (SHIV) in rhesus macaques [12]. Mascola et al., have reported that high-doses of 
broadly neutralizing antibodies provided an effective protection against mucosal HIV transmission 
[12]. Following the passive transfer of neutralizing antibodies, an analysis of mucosal secretions 
showed that these antibodies were able to transudate in the mucosal compartments (nasal, oral and 
vaginal mucosa), suggesting greater protective activity against the infection of macaques via the 
vaginal route [12]. Baba et al., also showed that the passive transfer of neutralizing IgG to new-born 
primates protects against oral SHIV transmission, suggesting a role for these neutralizing IgG in the 
inhibition of vertical HIV transmission from mothers to infants [11]. Another report showed that the 
passive transfer of the monoclonal neutralizing antibodies 2F5 and 2G12, which have broad 
neutralizing activity against primary HIV isolates [77], together with a purified polyclonal IgG 
obtained from the plasma of HIV patients, prevented intravenous SHIV infection in macaques [13]. 
Several other studies have also described that the passive administration of neutralizing monoclonal 
antibodies to non-human primates before or after viral challenge can protect the animals against 
infection [78]. Nishimura et al., showed that the passive transfer of neutralizing antibodies one hour 
following the infection of the primates, rather than 24 hours, conferred an increased effectiveness of 
protection [15]. The presence of these neutralizing antibodies before the establishment of infection 
seems to be the key determinant of the efficacy of antibodies. The initial studies in macaques 
highlighted the role of such neutralizing IgG in mucosal protection, but the use of progesterone to thin 
the cervico-vaginal surfaces may improve the transudation of these antibodies into mucosal fluid, 
thereby conferring a higher level of infection. Therefore, it has been speculated that, in the absence of 
hormone treatment, higher concentrations of systemic neutralizing IgG may be needed for efficient 
mucosal protection. However, this notion has been recently reconsidered, following the report from 
Ann Hessell et al., that low doses of neutralizing 2G12 antibodies protected rhesus macaques against 
experimental mucosal challenge [55]. This protection does not seem to be due to higher levels of 2G12 
transudation or transport from blood to the vaginal mucosal surface following intravenous antibody 
administration in macaques. The authors also determined the capacity of 2G12 to induce ADCVI and 
showed that 2G12 promoted ADCVI less efficient than IgG1  b12. Nevertheless, Fc-mediated 
inhibitory activities, other than ADCVI or ADCC, including phagocytosis and the clearance of 
immune complexes, were not evaluated. It therefore remains possible that 2G12 may compensate its 
neutralizing activity by other “extra-neutralizing activities”. Taken together, these data strongly Viruses 2009, 1                  
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suggest that higher doses of neutralizing antibodies are not necessary to confer a sterilizing protection 
in macaques and that other mechanisms of HIV protection, different from the neutralization, are 
certainly involved [79]. On the other hand, it has been suggested that the vaginal inoculation of 
macaques with large amounts of virus is not representative of the physiopathological conditions 
underlying sexually transmitted infection. Mostly, sexual HIV infection in human has occurred after 
multiple exposures to the virus, suggesting that repeated administration of low doses of virus inoculum 
in non-human primates may be the most appropriate model for studying the capacity of HIV-specific 
antibodies to prevent mucosal infection. Another recent report from the group of Dennis Burton 
suggested that the repeated passive administration of low levels of monoclonal neutralizing IgG1 b12 
antibodies was sufficient to protect macaques against the repeated low-dose exposure of SHIV to the 
mucosal surfaces of the vaginal walls [76]. 
4.2. Mechanism of protection-mediated by neutralizing IgG: role of FcRs 
Dennis Burton and his group have recently demonstrated that neutralizing monoclonal IgG1 b12, in 
the absence of Fc-FcR functions, cannot efficiently protect macaques from vaginal infection, 
indicating that FcRs are crucially involved in the mechanism of antibody protection against vaginal 
SHIV challenge [61]. Given to these data, it is the most evidence that FcRs are important in the 
mechanism of protection-mediated by neutralizing antibodies. When analyzing HIV neutralization on 
monocyte-derived macrophages and dendritic cells, an enhancement of the neutralizing activity was 
also detected for the five well-known monoclonal neutralizing IgG [21], but not for their 
corresponding neutralizing Fab fragments [21,60], indicating that the Fc portion of the these IgG as 
well as the FcRs are strongly implicated in this increased neutralization [21,22]. Of note under these 
conditions, a higher neutralizing or inhibitory activity of neutralizing 2F5 and 4E10 than of IgG1 b12 
was detected, suggesting that the conserved epitopes on gp41 are more relevant than the CD4 binding 
site epitope for neutralization of macrophages infection. Much like these findings, recently Perez et al., 
also observed that the neutralization activities of both monoclonal neutralizing 2F5 and 4E10, and, 
other plasma samples from chronically HIV-infected blood donors containing gp41 MPER-specific 
antibodies were potentiated by FcRI and, to a lesser extent, by FcRIIb [60]. In vitro, these recent 
data have also emphasized the role of FcRs in the mechanism of HIV inhibition by neutralizing IgG. 
As another example, previous studies have also confirmed that the passive transfer of monoclonal 
antibodies directed against West Nile virus cell surface-associated proteins triggers Fc receptor-
mediated phagocytosis and the clearance of infected cells and thus protection [80-82]. Altogether, 
these previous studies highlight the potent role of the Fc moiety of the IgG in the in vivo protection and 
in vitro inhibition afforded by the neutralizing antibody and raise questions about the effector 
functions induced by their cognate FcRs present at the cell surface of specific immune cells.  
As proof-of-concept, all these numerous passive transfer studies of neutralizing monoclonal 
antibodies have shown that administration of broadly reactive antibodies in non-human primates can 
afford sterilizing protection from vaginal or systemic infection [11-13,15,61,74,75,83], demonstrating 
the potential role of virus-specific humoral immunity [78]. In an important way, the recent studies in 
non-human primates also emphazised that FcRs play a crucial role in the mucosal protection against 
infection by neutralizing antibodies [61]. Viruses 2009, 1                  
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5. Non-neutralizing inhibitory IgG against HIV as antiviral antibodies 
5.1. Role of non-neutralizing IgG in HIV infection 
Unlike neutralizing antibodies, non-neutralizing antibodies, which are found in many HIV patients, 
are induced during the acute phase of HIV infection and generally before the induction of cross-
neutralizing antibodies. They may be generated by immunization or vaccination. Their role in HIV 
infection in vitro and in vivo was poorly understood or is somewhat controversial. Conversely, several 
groups have reported an FcRs-mediated antibody-dependent enhancement (ADE) of infection in 
vitro, which they attributed to the action of non-neutralizing antibodies [84-89]. Takeda et al., showed 
that subneutralizing concentrations of antibody-positive sera increased HIV replication in the U937 
human monocytic cell line [84], whereas optimal antibody concentrations did not. Others have shown 
that by blocking FcRIII, but not FcRI or FcRII, inhibit the enhancement of HIV infection in 
peripheral blood macrophages [85,86]. By contrast, FcR-independent ADE of HIV infection in MT2-
CD4
+ T lymphoblastoid cells has been detected in a small proportion of serum samples from HIV-
seropositive individuals [90], suggesting that there may be several modes of ADE. One paper to date 
has described the ADE of HIV infection in FcR-expressing cells [91]. Complement-dependent ADE 
has also been observed in certain types of dendritic cells (reviewed in [92]). 
Preliminary studies have reported that the neutralizing activities of polyclonal IgG purified from the 
plasma or sera of SIV-infected macaques or HIV-infected patients are increased by a factor of 100 to 
1,000-fold when monocyte-derived macrophages instead of blood mononuclear cells are used as target 
cells of virus [16,17]. Interestingly, they have reported that some purified IgG samples from the sera of 
recently infected individuals (a few months after seroconversion) or from recently infected macaques 
(six months after SIV inoculation) have potent neutralizing or inhibitory activities on macrophages and 
not on PBMCs. This suggests that non-neutralizing antibodies, which are produced before neutralizing 
antibodies, may play a role in the early stages of infection. More recently, it has been reported that 
non-neutralizing antibody activities were correlated with the reduction of acute viremia in vaccinated 
macaques [93], demonstrating that non-neutralizing antibodies-elicited by immunization could play an 
important role in the control of the acute phase of infection mediated, at least in part, by ADCVI 
activity and transcytosis inhibition. 
5.2. FcRs-mediated HIV inhibition by antibodies: role of non-neutralizing inhibitory IgG? 
Although a role of the FcRIII in the mechanism of HIV inhibition by antibodies, independently of 
the CD4 receptor, has been described in macrophages [86], we [21] and, more recently, the group of 
David Montefiori [60], have definitively demonstrated that human FcRs are involved in the inhibition 
of HIV replication by some HIV-specific IgG in human blood monocyte-derived macrophages and in 
transformed TZM-bl cells expressing various FcRs, respectively. Others have shown that the 
activation of human macrophages, through FcRs cross-linking, can contribute to the natural 
protection against HIV infection observed in some HIV-exposed uninfected individuals by inhibiting 
mucosal virus transmission [94]. Some time ago, the team of Michael Fanger evaluated the role of 
FcRs in the infectivity of monocytes and macrophages, using bispecific antibodies to target HIV Viruses 2009, 1                  
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particles to various FcR-bearing cells; they found that these FcRs were not involved in the ADE of 
HIV infection in these cells [95]. 
In vitro some non-neutralizing IgG (monoclonal or polyclonal antibodies from HIV-1 patients) 
strongly inhibit HIV replication in macrophages or dendritic cells generated from human blood 
monocytes [21-23]. In addition, it has also been demonstrated that HIV infection and provirus 
formation are impaired in immature dendritic cells in the presence of HIV-specific IgG and 
complement [96]. The long-term transfer of HIV from dendritic cells to CD4 T cells also seems to be 
impeded by these HIV-specific IgG, whereas the addition of these antibodies and/or complement to 
activated PBMC did not protect them from HIV infection. It has thus been concluded that 
unconventional mechanisms of HIV inhibition by such antiviral antibodies may take place in dendritic 
cells but not in PBMC, leading to the suggestion that the lower levels of infection mediated by HIV-
IgG immune complexes may result from interactions of virus-bound IgG with FcRIIb expressed on 
DCs [96]. 
The Fab domain and the Fc constant domain of IgG and FcRs present at the membrane of these 
APCs are involved in the efficient inhibition of HIV-1 replication in these immune cells by 
monoclonal and polyclonal non-neutralizing inhibitory IgG. More interestingly, we have reported that 
some monoclonal non-neutralizing IgG recognized specific epitopes on the viral gp, particularly in the 
V3 loop regions of gp120 and certain domains of gp41 (e.g., the immunogenic principal immuno-
dominant domain) [23]. For some of them, their inhibitory concentrations that reduced 90% of 
infection are of similar magnitude that those of monoclonal neutralizing antibodies when these FcR-
bearing immune cells are used as HIV targets cells. These non-neutralizing inhibitory antibodies 
possess unconventional antiviral activities on FcR-bearing immune cells. Such antibodies (some non-
neutralizing inhibitory IgG as well as the monoclonal neutralizing IgG1 b12 for example) are not 
detected in the new neutralization assay performed with FcR-expressing TZM-bl cells [60], 
undoubtedly due to differences in viral epitope-antibody recognition or host-cell susceptibility to HIV 
infection (high levels of expression of CCR5) or that these cell lines express only one of each FcR 
subtype and not a combination of multiple FcRs.  
For example, it has been reported that the level of CCR5 expression, but not of CD4, on cell surface 
of HeLa cells may modify the neutralization efficiency of certain 4E10-like neutralizing antibodies 
[97]. These unconventional inhibitory IgG, despite being unable to neutralize free viral particles in the 
conventional neutralization assay, display potent FcR-mediated HIV inhibition in other 
unconventional assays [20]. Effectively, the Fc portion of these anti-HIV antibodies may bind to the 
corresponding FcRI or II on the cell surface of these APCs, thereby mediating HIV inhibition by a 
mechanism involving the phagocytosis and clearance of HIV-IgG immune complexes. This 
mechanism of HIV inhibition, distinct from the neutralization of the infectious viral particles by the 
Fab part of the antibody, exploits FcγR functions induced by IgG. 
Other non-neutralizing antibodies recognizing epitopes present on the V2 loop, the C5 constant 
region or the CD4 binding site of HIV cannot prevent HIV replication in APCs [23]. Recently, using 
cord blood CD34-derived Langerhans and interstitial dendritic cells as HIV target cells, we confirmed 
that FcRs are involved in HIV inhibition by neutralizing as well as non-neutralizing inhibitory 
antibodies (personal communication, unpublished results). No antibody-dependent enhancement of 
HIV replication has been detected in this in vitro inhibitory assay when macrophages or dendritic cells Viruses 2009, 1                  
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are used as HIV target cells. These data support the view that other types of HIV inhibition mechanism 
are implicated, and, point out that new assays need to be set up to understand the underlying 
mechanism of action. 
Figure 1. Mechanisms of antibody-dependent FcRs-mediated HIV inhibition. A 
schematic overview of the role of FcR-bearing cells, such as macrophages or immature 
dendritic cells, in the mechanism of HIV inhibition by neutralizing and non-neutralizing 
inhibitory IgG. Macrophages and dendritic cells located at the portal of HIV entry, and 
other immune cells present in the blood, such as NK cells may play an important role in 
preventing the establishment of HIV infection. Some macrophages and dendritic cells can 
degrade free-viral particles by phagocytosis for antigen presentation, but these cells are 
also permissive to the virus and can produced de novo viral particles. Due to the expression 
of FcRs, including FcRI and II in particular, at the cell surface of these cells, neutralizing 
and non-neutralizing inhibitory IgG can inhibit HIV infection by a mechanism of antibody-
dependent phagocytosis leading to viral degradation in an endolysosomal compartment 
within these antigen-presenting cells (APCs). In addition, FcRIII may play a role in the 
killing of infected cells by an ADCC-based mechanism. Moreover, FcRI has been 
reported to mediate ADCC by neutrophils. 
(1) There is no clear evidence that dendritic cells 
could mediate ADCC, unlike they express low levels of FcRIII. Besides, this FcR has 
also been reported to inhibit viral replication by a mechanism of ADCVI mediated by other 
cells, such as NK cells, monocytes and neutrophils. This figure illustrates the key role 
played by FcRs in the mechanism of HIV inhibition by neutralizing antibodies and by 
some specific antiviral antibodies. 
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Moreover, Donald Forthal and teammates have shown that NK cells and the Fc part of polyclonal 
IgG are required for the enhanced HIV-1 inhibition in PBMCs [98]. They also recently published that 
recombinant gp120 vaccination can elicit antibodies with antiviral
 activity against clinical strains of 
HIV-1, which necessitate the presence of FcR-bearing effector NK cells [99]. They found that these 
antibodies inhibited HIV infection in the presence of effector cells, such as NK cells or Fc-bearing 
cells, whereas F(ab’)2 fragments of these antibodies did not protect permissive cells against infection 
more effectively than whole IgG. A correlation has been found between the level of ADCVI and the 
gene polymorphism of FcRIIa and FcRIII. 
In addition to the neutralizing activity of antibody, Fc-FcR interactions are essential for in vivo 
protection against HIV infection. For these reasons, antibody-mediated effector mechanisms other than 
neutralization are clearly of great importance in protection against HIV [100]. The mechanisms by 
which FcRs can enhance the HIV inhibitory activities of such antibodies remain unclear. However, 
FcR-bearing immune cells involved in first-line defenses against mucosal HIV transmission are likely 
to play an important role in the clearance of opsonized virus by specific antibodies (Figure 1). The in 
vivo relevance of such non-neutralizing inhibitory or antiviral antibodies mediating FcR effector 
functions remains to be clarified. 
5.3. HIV inhibition by antibody-dependent cell cytotoxicity (ADCC) 
Several studies have shown that ADCC is one mechanism through which HIV-specific antibodies 
can limit or control viremia during HIV infection; such antiviral antibodies are often detected in the 
plasma of acutely infected patients [101-105], whereas neutralizing antibodies are generally absent. 
Unlike neutralizing activity, ADCC activity is detectable in most of HIV-infected individuals within a 
few days after seroconversion, and is correlated with the decline of the viremia [104]. ADCC activity 
can also be involved in disease progression, as non progressors, unlike rapid progressors, have high 
levels of ADCC antibodies [106]. Other HIV-infected individuals with undetectable levels of virus 
also have higher titers of such antibodies than viremic subjects [107]. Similarly, ADCC activity has 
recently been detected in HIV controllers at significantly higher levels than in viremic individuals 
[108]. In macaques, ADCC has also been correlated with delayed progression to AIDS, confirming the 
previous observations in humans [109,110]. Dysfunction NK cell activity has been reported in HIV-
infected individuals [111]. The NK cells of infected patients produce IFN- but are unable to mediate 
ADCC in vitro [112]. In infected patients treated by HAART, a subset of blood cells expressing NK 
markers have been reported to display persistent HIV infection [113], suggesting that NK cells may 
serve as a reservoir for the virus. Other studies have also reported that HIV may modify the ADCC 
function of macrophages and neutrophils [114]. To date, various ADCC assays have been developed to 
analyze more precisely the activity of such antibodies to kill HIV infected cells, as reviewed in [115]. 
More recently, as HIV-specific ADCC antibodies triggered multiple effector functions of NK cells 
upon FcRIII cross-linking (e.g., IFN-, TNF-and  -chemokines production, degranulation of 
perforin and granzymes, CD107a expression, etc.)[116], new assays have been setup to monitor 
directly the activation status of the NK cells. According to the literature, all these compounds have 
antiviral activity and can directly interfere with HIV infection or infected cells. Viruses 2009, 1                  
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Several ADCC epitopes on HIV have been identified, some of which are present in many HIV-
infected individuals [114]. V3 loop ADCC epitopes appear to be the major determinants for ADCC 
activity, but ADCC epitopes in the V2 domain of gp120 have also been defined. It seems likely that 
the presence of ADCC epitopes in a variable region may result in viral variants escaping ADCC 
responses. Thus, analyzing of viral escape from ADCC activities would identify a subset of conserved 
ADCC epitopes. No clear correlations between vaccine-induced ADCC responses and in vivo 
protection have yet been observed, but most of the available evidence suggests that ADCC responses 
control HIV infection.  
The role of ADCC in vaccination has been evaluated. Mucosal prime systemic boost immunization 
of macaques can elicit both ADCC and neutralizing antibodies, but protection against mucosal SHIV 
challenge is correlated with the titers of neutralizing antibodies, rather than with those of ADCC 
antibodies [114,117]. Others studies have reported that titers of human rgp120 vaccine-induced FcR-
dependent antibodies, which inhibit HIV infection in vitro, are inversely correlated with the infection 
rate [99]. It is thus important to determine which types of HIV-specific ADCC antibodies are required 
to prevent HIV infection and the likelihood of their induction by vaccination. It is well known that 
non-neutralizing antibodies, that mediated ADCC responses, can potentially contribute to mucosal 
defense against HIV, if present in cervico-vaginal secretions [118,119]. 
5.4. Antibody-dependent cell-mediated virus inhibition (ADCVI) 
Like ADCC, antibody-dependent cell-mediated virus inhibition or ADCVI results from an 
interaction between an infected target cell, a HIV-specific antibody and an effector cell expressing one 
or several FcRs. Unlike ADCC, ADCVI reflects the impact of antibody and effector cells on viral 
replication [61,99,104,120]. ADCVI encompasses multiple effector function activities related to lytic 
(e.g., ADCC) and non-cytolytic (e.g. production of -chemokines, etc.) mechanisms dependent on 
FcRs that may interfere with HIV infection and replication. In vivo, the ADCVI activity of non-
neutralizing antibodies may help to reduce viral load and is strongly correlated with Fc-FcR-mediated 
HIV inhibition by neutralizing antibodies in vitro [55,61]. ADCVI may be a reliable indicator of the 
antiviral activity of non-neutralizing antibodies that are not detected in conventional neutralization 
assays. 
6. Neutralizing IgA as mucosal immunity against sexual HIV transmission 
Twenty years ago, it has been described that HIV-specific immunity could be detected in antibody-
positive and antigen-negative sexual partners of known HIV-seropositive individuals [121,122]. Since, 
intensive investigations of the epidemiologic, genetic and immune characteristics of this minority 
group of individuals, either women or men, such as sexual partners of many different HIV-infected 
persons, commercial sex workers, healthy newborns of HIV-infected mothers or some drug users, who 
remained uninfected despite repeated exposure to HIV, have been carried out by several international 
HIV research groups. The observation of resistance to HIV infection in these highly HIV-exposed 
individuals has attracted the curiosity of the scientific community over the years. For many reports, the 
lack of infection in these individuals may be associated with the exclusive priming of T lymphocytes 
[122]. Subsequent reports showed that a particular genetic background or the presence of soluble HIV Viruses 2009, 1                  
 
 
1281
inhibitor factors, or cytotoxic T lymphocytes and a potent NK cells activity can be detected in mucosal 
fluids, potentially accounting for this resistance to HIV infection [122]. 
The presence of HIV-specific IgG and IgA has also been examined in the cervico-vaginal samples 
and plasma of HIV-exposed uninfected subjects (mainly women from Italy, India, Kenya, Thailand, 
Cambodia,  etc.)  versus infected people. Several studies have shown that HIV-specific IgA were 
present in the genital tract of some HIV-uninfected heterosexual partners of seropositive individuals 
[123-130]. These subjects have been referred as highly sexually exposed to HIV-1 but persistently IgG 
seronegative or HEPS. The presence of mucosal IgA has been observed in several but not all groups of 
HEPS subjects [131,132]. HIV-specific IgA has also been detected in the seminal fluid of male 
seronegative partners of HIV-positive women [133]. Moreover, in some infants of infected mothers, 
HIV-specific salivary IgA have been observed [134]. It has been proposed that the CCL28 chemokine 
may preferentially attract and increase the rate of IgA-secreting plasma cells in the epithelial lamina 
propria, thereby increasing the amount of specific IgA produced. By contrast, in many HIV-infected 
persons, HIV-specific IgG and IgA were found in plasma and mucosal samples. None of the HIV-
resistant sex workers had HIV-specific systemic and mucosal IgG responses. The absence of 
detectable HIV-specific IgG in the sera of these HEPS remains puzzling, because of the conventional 
view of Ig class-switching. This discrepancy may result from technical issues relating to the detection 
of IgA in mucosal fluids and the methods used for the collection of these fluids. In 10% of the HIV-
exposed uninfected female sex workers, HIV-specific mucosal IgG were detected in the absence of 
mucosal viral antigen-specific IgA were detected [132]. However, these uninfected women had no 
detectable HIV-specific IgG in their plasma. These findings suggest that some uninfected female sex 
workers may have developed low-level mucosal IgG responses against HIV. In some circumstances, 
the frequency of genital tract IgA may be underestimated with the respect to that of IgG due to 
antibody competition for HIV binding sites [135] and the mucosal environment (local bacterial 
infection, IgA1 protease activity, genetic differences, etc.). In such cases, co-infected individuals may 
have a transient IgA deficiency at the mucosal surface, without being susceptible to the acquisition of 
HIV-infection. HIV-specific Th responses have been associated with HIV resistance in some cases, in 
several cohorts of HEPS patients [124,136,137]. However, these cellular responses are not correlated 
with HIV-specific mucosal IgA responses, consistent with systemic cellular and mucosal humoral 
responses being independent mechanisms of protection against HIV infection. The genital mucosae are 
enriched in lymphoid follicules specializing in the development of IgA-producing plasma cells. Thus, 
mucosal HIV-specific IgA immunity may rapidly become estalished locally, resulting in the 
containment of HIV infection (thus preventing IgG seroconversion), independently of host cellular 
responses. It has been proposed that the signaling pathway required for systemic IgA responses, which 
seem to be dependent on the germinal center, are strikingly different from those of mucosal IgA 
responses. 
It has recently been shown that the presence of mucosal monoclonal IgA antibodies specific for 
HIV gp41 is a correlate of protection in some HEPS individuals. These HIV gp41-specific IgA have 
been characterized: they are able to neutralize HIV and inhibit HIV transcytosis. Their Fab domain has 
a specificity similar to that of the broadly neutralizing monoclonal IgG antibodies 2F5 and 4E10 [138]. 
Polyclonal HIV-specific IgA purified from the sera of asymptomatic HIV patients has been shown to 
display HIV neutralizing activities, as detected in the conventional neutralization assay using Viruses 2009, 1                  
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peripheral blood leukocyte population as HIV target cells [8]. As for these polyclonal neutralizing IgA, 
the neutralizing titers of these gp41-specific IgA from HEPS patients are closed to those of 
neutralizing IgG 2F5, indicating that the presence of low doses of these neutralizing IgA in genital 
secretions may be active in vivo [138]. Relative to the specificity of epitope targeted by these IgA, the 
recognized region of gp41 seems to be in conformational configuration and conserved between clade B 
and C HIV strains. As antibody maturation is a process of great importance for the neutralizing activity 
of IgG, one may expect that HEPS individuals, which are subjected to repeat unprotected intercourse 
and frequent exposure to HIV over a period of months or even years, might therefore be expected to 
develop potent affinity-matured IgA with neutralizing activity. The HIV seronegativity of these HEPS 
women is correlated with the production of large amounts of neutralizing IgA in the genital tract and a 
systemic proliferative response in circulating blood leukocyte populations [125]. These data 
highlighted the possible involvement of these both independent types of immunity in the protection 
against sexual HIV transmission. 
7. Conclusions and Future Directions 
In the world, HIV is transmitted mainly by sexual ways. Like other sexually transmitted diseases, 
HIV infects individuals through the sexual mucosae, particularly in the female genital tract, which 
constitutes one of the major portals of viral entry. Thus, the induction of protective mucosal immunity 
is an important goal of future HIV vaccine design. The production of HIV-specific antibodies that are 
able to prevent sexual HIV transmission is a major challenge for HIV vaccine development. As 
neutralizing antibodies have been shown to inhibit HIV replication in vitro and have been correlated 
with protection against sexual HIV infection in vivo, the induction of such antibodies by vaccination is 
of prime importance. The development of an effective vaccine able to induce the production of such 
antibodies would undoubtedly be the best solution for the control of the worldwide AIDS pandemic. 
None of the various prototype of HIV-1 vaccine candidates designated to elicit humoral and/or cellular 
immunity has yet afforded protection against infection or decreased viral load after infection [139]. 
Excepted for the Thai Phase III HIV vaccine clinical trial, it is the first demonstration that a safe and 
effective AIDS vaccine candidate provides partial benefit in humans. Today, we need to understand 
why this vaccine regimen worked. After the failure of the Merck HIV vaccine, these results give new 
hope for the development of a future protective vaccine against HIV. 
Many efforts have been made to understand the mechanism underlying the induction of neutralizing 
antibodies, but so far, they have been largely unsuccessful. One may assume that resolving the 
mechanism of development of such antibodies will provide critical guidance for pertinent new vaccine 
strategies. Eliciting neutralizing antibodies by immunization is already one of the main goals of the 
vaccine research. Current approaches based on AAV encoding gene transfer of neutralizing antibodies 
have made it possible to induce, in vivo, an efficient humoral immune response specific for HIV. The 
results obtained have important implications for future research aiming to develop new methods of 
immunization.  
For the design of new vaccination strategies or approaches, including mucosal vaccination in 
particular, we need to determine the role of the specific immunity (production of neutralizing IgA) of 
cervico-vaginal tissue and its relation with the systemic immunity needs to be clarified. The precise Viruses 2009, 1                  
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role of HIV-specific neutralizing IgA in the prevention of mucosal HIV transmission needs further 
investigation; in particular to evaluate if passive infusion of such antibodies could protect from vaginal 
challenge in non-human primate model. The recent findings that the repeated passive administration of 
low doses of cross-neutralizing antibodies can confer protection in macaques repeatedly infected 
vaginally with low levels of viral inoculum has overturned previous notions that high titers of such 
antibodies are required to generate sterilizing protection against HIV infection.  
The demonstration that FcRs play a crucial role in the neutralizing antibody-mediated protection in 
macaques has indicated that the Fc portion of such antibody is essential in this protection and not only 
the neutralizing Fab part. These data have helped to clarify the role of FcRs in antibody-mediated 
HIV protection and to upgrade our overall understanding of how neutralizing antibodies work and how 
they can be induced by immunization. They have also highlighted the need to develop new types of 
antibody with a higher Fc-FcR interaction affinity, to increase the efficacy of protection against 
infection. 
The detection of antiviral or inhibitory activities of some non-neutralizing IgG antibodies has 
highlighted the need to develop new neutralization assays and raises the question of the relevance of 
these antiviral antibodies in the protection in vivo. Not only neutralizing antibodies are highly 
important in rational vaccine research and design, non-neutralizing inhibitory antibodies, which 
mediated FcRs-dependent mechanism of HIV inhibition, should be one of the important components 
to take into account for further development of novel immunogens to include in future vaccinal 
preparations. 
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